Fig. 1 · Structure

Documents & Downloads

Elesclomol (STA-4783)

Cat. No. A10343 CAS 488832-69-5
Elesclomol induces oxidative stress by provoking a buildup of reactive oxygen species within cancer cells.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Elesclomol–copper exposure produced concentration-dependent changes in cuproptosis-associated proteins in H9c2 cells: reduced lipoylated DLAT/DLST and selected Fe-S protein signals, with increased higher-order DLAT complexes at higher concentrations. ACO2 did not show the same reduction. These results concern the copper complex and do not establish a universal death mechanism for the uncomplexed ligand. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
HSP70 (Cell-free assay)

Cellular Effect

Cell Line Activity Value Description Reference
Ramos EC50 0.02 μM Induction of Hsp70 production in human Ramos cells after 5 hrs by ELISA [PMID: 23937981]

Elesclomol (STA-4783) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Elesclomol (STA-4783) from 3 published references. In vitro models include human HBL melanoma cells and mitochondrial-DNA-depleted HBL-rho0 cells; rat H9c2 wild-type and Ctr1-knockout cells.

Elesclomol (STA-4783) In Vitro Studies

In HBL melanoma cells, 300 nM elesclomol–copper increased ROS-probe oxidation at 12 h and cell death at 24 h. Mitochondrial-DNA-depleted HBL-rho0 cells were resistant under the same conditions, and copper alone did not reproduce the cell-death response. [2]

In copper-deficient H9c2 Ctr1-knockout cells, elesclomol–copper restored COX1 abundance at concentrations below those reducing ATP-based viability. At 48 h, the COX1-restoration EC50 was 0.5 nM and the viability IC50 was 26 nM. These are distinct cellular endpoints, not treatment doses or a clinical safety margin. [1]

ETC dependence of elesclomol–copper responses in melanoma cells

Cell-based study · Human HBL melanoma cells and mitochondrial-DNA-depleted HBL-rho0 cells [2]

At 300 nM elesclomol–Cu, parental HBL cells showed increased probe oxidation at 12 h and cell death at 24 h; HBL-rho0 cells were resistant under these conditions. Copper alone did not reproduce cell death. These results establish dependence on the tested cellular mitochondrial state, without identifying a single direct protein target or proving that all elesclomol-induced death is apoptotic.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Probe oxidation in parental versus rho0 melanoma cellsqualitative response Increased in parental HBL; no corresponding induction in HBL-rho0[2]
Cell death compared with untreated and copper-only controlsqualitative response Cell death induced in parental HBL but not HBL-rho0; copper alone had no effect under these conditions[2]

Literature-Reported Treatment Conditions

Treatment concentration
300 nM elesclomol–Cu; copper-only comparator at 300 nM
Exposure duration
12 h for ROS probe; 24 h for cell-death analysis
Method
Flow cytometry: hydroxyethidium oxidation and propidium iodide staining; Figure 5 also displays DiOC6(3).
Vehicle
Untreated controls shown; solvent concentration for this experiment is not specified in the relevant subsection.
Reported limits
Do not borrow the 0.3% DMSO used for the separate Hs294T combination assay. Figure 5A is representative of three independent experiments; Figure 5B does not separately state replication.
Methods and source locations

Compound reported in the paper: Elesclomol; Compound label in the paper: Elesclomol–copper complex (elesclomol-Cu)

Applies to elesclomol supplied with copper as the tested complex; not a ligand-alone potency claim.

Results: Human cells lacking ETC activities are insensitive to elesclomol; Figure 5A–B; Methods: Reagents and Cytofluorometric analyses of rho0 Melanoma Cell Lines

Probe oxidation in parental versus rho0 melanoma cells: Hydroxyethidium flow cytometry after 300 nM elesclomol-Cu for 12 h; representative of three independent experiments — Figure 5A and corresponding Results/Methods

Cell death compared with untreated and copper-only controls: Propidium iodide flow cytometry after 24 h; Figure 5B also shows mitochondrial-potential dye — Figure 5B and corresponding Results/Methods

COX1 restoration and viability concentration responses in copper-deficient cells

Cell-based study · Rat H9c2 wild-type and Ctr1-knockout cells [1]

ES-Cu restored COX1 abundance in copper-deficient Ctr1-knockout cells at lower concentrations than those that reduced ATP-based viability. At 48 h, the COX1-restoration EC50 was 0.5 nM, whereas viability IC50 values were 25 nM in WT and 26 nM in knockout cells. This assay-specific separation is not a clinical therapeutic index.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ATP-based cell viability after ES-Cu treatmentIC50 24 h: WT 32 nM, Ctr1−/− 36 nM; 48 h: WT 25 nM, Ctr1−/− 26 nM; 72 h: WT 19 nM, Ctr1−/− 19 nM[1]
Restoration of COX1 abundance in Ctr1-knockout cellsEC50 24 h: 0.5 nM; 48 h: 0.5 nM; 72 h: 0.2 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Viability: 0.1, 0.5, 1, 5, 10, 50 and 100 nM; COX1: 0.1, 0.5, 1 and 5 nM ES-Cu
Exposure duration
24, 48 and 72 h
Method
CellTiter-Glo ATP-based viability; SDS-PAGE/immunoblotting for COX1 normalized to ATP5A and vehicle control.
Vehicle
DMSO (≤0.1%)
Methods and source locations

Compound reported in the paper: Elesclomol; Compound label in the paper: Elesclomol–copper complex (ES-Cu)

Complex-specific cellular assay endpoints; COX1 abundance is a protein-rescue readout, not direct enzyme activity.

Results 3.1; Figure 2A–K; Methods 2.1, 2.2, 2.5, 2.6, 2.10

ATP-based cell viability after ES-Cu treatment: CellTiter-Glo; fitted concentration-response values; n = 3 biological replicates with three technical replicates; data expressed as mean ± SD — Figure 2A–D (values printed in D); Methods 2.5 and 2.10

Restoration of COX1 abundance in Ctr1-knockout cells: COX1 immunoblot signal normalized to ATP5A and vehicle; n = 3 biological replicates, mean ± SD — Figure 2E–K (values printed in K); Results 3.1; Methods 2.6 and 2.10

Concentration dependence of copper-toxicity protein markers

Cell-based study · Rat H9c2 wild-type and Ctr1-knockout cells [1]

After 18 h of ES-Cu exposure, lipoylated DLAT/DLST and selected Fe-S protein signals decreased with concentration, while higher-order DLAT complexes increased at higher concentrations. ACO2 was an exception: its abundance did not show the corresponding reduction and an IC50 was not determined. These are cuproptosis-associated molecular readouts; the experiment does not establish an exclusive death pathway.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Reduction in immunoblot abundance of Fe-S proteinsIC50 WT / Ctr1−/− (nM): SDHB 7.0 / 10.6; UQCRFS1 8.7 / 16.2; LIAS 6.2 / 7.4; ACO2 N.D. / N.D.[1]
Reduction in lipoylated DLAT and DLST signalsIC50 WT / Ctr1−/− (nM): Lip-DLAT 5.3 / 6.4; Lip-DLST 3.4 / 3.2[1]
Increase in higher-order DLAT immunoblot bandsEC50 WT 28.6 nM; Ctr1−/− 33.9 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0 (DMSO), 1, 5, 10, 25, 50 and 100 nM ES-Cu
Exposure duration
18 h
Method
Immunoblot concentration-response analysis of Fe-S proteins and lipoylated proteins; nonreducing electrophoresis/immunoblotting for DLAT oligomers.
Vehicle
DMSO; cell-culture stock described in Methods 2.1; exact final solvent percentage for Figure 4 is not separately specified.
Reported limits
Uncropped SI blots and fitted-data supplement were not retrieved. No unreported precision or confidence interval is assigned to printed point estimates.
Methods and source locations

Compound reported in the paper: Elesclomol; Compound label in the paper: Elesclomol–copper complex (ES-Cu)

Complex-specific molecular-marker responses in rat cells, not ligand-alone biochemical inhibition constants.

Results 3.3; Figure 4A–I; Methods 2.1, 2.2, 2.6, 2.10

Reduction in immunoblot abundance of Fe-S proteins: 18 h; immunoblot band-intensity fits; ATP5A and beta-actin controls; n = 3 biological replicates; N.D. means not determined — Figure 4A–C (printed table C); Results 3.3; Methods 2.10

Reduction in lipoylated DLAT and DLST signals: 18 h; anti-lipoic-acid immunoblot concentration-response fits; n = 3 biological replicates — Figure 4D–F (printed table F); Results 3.3; Methods 2.10

Increase in higher-order DLAT immunoblot bands: 18 h; nonreducing immunoblots; combined bands above 75 kDa normalized to vehicle; n = 3 biological replicates — Figure 4G–I (printed table I); Results 3.3; Methods 2.10

Elesclomol (STA-4783) In Vivo Studies

In intestine-specific Ctr1-knockout mice, oral elesclomol at 10 mg/kg every 2 days from postnatal day 7 to 31 was associated with 100% survival through day 35 (n = 4), whereas vehicle-treated knockouts died between days 12 and 23 (n = 5). No copper was added to treatment. The report contains an unresolved methylcellulose-formulation discrepancy, and this intestinal Ctr1 model does not establish efficacy in mammalian ATP7A deficiency. [3]

Oral elesclomol in intestinal copper-transport deficiency

Animal study · Intestine-specific Ctr1-knockout mice and control littermates [3]

The study reported rescue of early lethality and improved growth with oral elesclomol without added copper supplementation. Survival was 100% through PND 35 in treated knockouts; vehicle-treated knockouts died by PND 23. Enterocyte CCS levels and excess total copper were reduced, while zinc was not significantly altered. The treated formulation has a methylcellulose-description discrepancy, and this model does not establish oral efficacy in mammalian ATP7A deficiency.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Survival of Ctr1-int/int mice through PND 35survival ES: 100% (n = 4); vehicle: all died between PND 12 and 23 (n = 5)[3]
Enterocyte CCS and total copper/zinc at PND 17qualitative group comparison CCS and excess copper reduced with ES; zinc not significantly changed[3]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Every 2 days
Treatment course
PND 7 through PND 31; survival and body-weight observation through PND 35
Vehicle
Elesclomol dissolved in DMSO and mixed with methylcellulose; exact treated formulation is ambiguous in the source.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Oral elesclomol in intestine-specific Ctr1-knockout mice
10 mg/kg body weight elesclomol
Ctr1-int/int vehicle group; littermate WT vehicle/ES groups for growth. Vehicle control reported as 0.5% methylcellulose with 2% DMSO.100% survival through PND 35 in ES-treated knockouts (n = 4); all vehicle-treated knockouts died between PND 12 and 23 (n = 5). ES-treated knockouts gained weight. Enterocyte CCS and copper measurements supported altered copper availability; zinc was not significantly changed.[3]
Oral elesclomol in intestine-specific Ctr1-knockout mice
Model: Ctr1-int/int mice; littermate controls were Ctr1-flox/flox or Ctr1-flox/+ without Cre
Reported limits: Methods describes mixing with a 5% methylcellulose solution but a 0.5% methylcellulose vehicle control; final treated methylcellulose percentage cannot be confidently reconstructed. Survival and weight cohorts have different n.
Methods and source locations

Compound reported in the paper: Elesclomol; Compound label in the paper: Elesclomol (ES), supplied by Selleckchem, without precomplexed copper

Applies to reported oral ligand dosing in Ctr1-deficient mice, without assuming Adooq lot validation or clinical applicability.

Mouse Results; Figure 4A–E; Methods: Elesclomol Gavage in Mice, Tissue Preparations and Antibodies, ICP-MS, Statistical Analysis

Survival of Ctr1-int/int mice through PND 35: Kaplan–Meier plot; oral dosing every 2 days PND 7–31 — Figure 4A; Mouse Results; Methods: Elesclomol Gavage in Mice

Enterocyte CCS and total copper/zinc at PND 17: CCS immunoblot normalized to GAPDH; ICP-MS; mean ± SD; figure shows group letters for ANOVA significance; no exact bar heights extracted — Figure 4C–E and caption; Mouse Results; Methods: ICP-MS

Oral elesclomol in intestine-specific Ctr1-knockout mice · Mouse Results; Figure 4A–E; Experimental Procedures: Elesclomol Gavage in Mice

Specifications

Manufacturer Adooq Bioscience
CAS Number 488832-69-5
Formula C19H20N4O2S2
Molecular Weight 400.5
Synonyms STA-4783
SMILES
CN(C(=S)C1=CC=CC=C1)NC(=O)CC(=O)NN(C)C(=S)C2=CC=CC=C2

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 77 mg/mL (192.26 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
5% DMSO+40%PEG300+5%Tween80??+50%H2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Elesclomol (STA-4783) Research References

  1. [1] Mohammad Zulkifli, Krishna P Maremanda, Adriana U Okonkwo, et al. Elesclomol rescues mitochondrial copper deficiency in disease models without triggering cuproptosis The Journal of Pharmacology and Experimental Therapeutics (2025). PMID: 40023603 DOI: 10.1016/j.jpet.2024.100048 Source material
  2. [2] Ronald K Blackman, Kahlin Cheung-Ong, Marinella Gebbia, et al. Mitochondrial Electron Transport Is the Cellular Target of the Oncology Drug Elesclomol PLoS ONE (2012). PMID: 22253786 DOI: 10.1371/journal.pone.0029798 Source material
  3. [3] Sai Yuan, Tamara Korolnek, Byung-Eun Kim. Oral Elesclomol Treatment Alleviates Copper Deficiency in Animal Models Frontiers in Cell and Developmental Biology (2022). PMID: 35433682 DOI: 10.3389/fcell.2022.856300 Source material

Added to your cart

View Cart Checkout
Loading...